FOXO4-DRI vs Tesamorelin
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
FOXO4-DRIGrowth Hormone PeptidesFat Loss & Metabolic
Tesamorelin- Summary
- FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
- Tesamorelin is an FDA-approved synthetic GHRH analog specifically indicated for reduction of excess abdominal (visceral) fat in HIV patients with lipodystrophy. It is the only GHRH peptide with FDA approval for a fat-reduction indication and is studied off-label for metabolic syndrome and cognitive function.
- Half-Life
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- ~26 minutes
- Admin Route
- Subcutaneous, Intraperitoneal (research)
- SubQ
- Research
- —
- —
- Typical Dose
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- 2 mg
- Frequency
- 3 consecutive days per cycle
- Once daily
- Key Benefits
- Selectively clears senescent cells (senolytics)
- Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
- Demonstrated restoration of physical fitness in aged mice
- May improve healthspan and reduce age-related tissue dysfunction
- Potential for treatment of age-related pathologies driven by cellular senescence
- Does not affect healthy non-senescent cells at therapeutic doses
- FDA-approved for visceral fat reduction in HIV lipodystrophy
- Significant reduction in trunk/visceral fat (average 15–20% in trials)
- Improved triglyceride and lipid profiles
- Potential cognitive benefits and memory improvement
- Preserves lean mass while reducing fat
- Natural pulsatile GH stimulation
- Side Effects
- Limited human data; largely preclinical evidence
- Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
- Weight loss observed at high doses in rodent studies
- Unknown long-term safety profile in humans
- Injection site reactions (redness, irritation)
- Arthralgia and joint pain
- Peripheral edema
- Carpal tunnel syndrome
- +2 more
- Stacks With
- —
- —